Strolll, a Stafford-based software-as-a-medical-device company building augmented reality neurorehabilitation tools, has secured £4.3m (€5m) from Innovate UK across a £3.6m innovation loan and a £700k grant, plus a separate equity round led by IW Capital with Cleveland Clinic and Future Planet Capital Regional participating.
Founded in 2018, Strolll delivers clinically validated, patented neurorehabilitation to patients with neurological disorders through AR glasses, in clinics and at home. It raised a €12.2m Series A in March 2025, also led by IW Capital.
The structure of this package is the interesting part. The two Innovate UK awards fund two distinct projects and are non-dilutive: a £3.6m (€4.18m) innovation loan and a £700k (€813.2k) Growth Catalyst Investor Partnerships award. Terms of the accompanying IW Capital-led equity round were not disclosed, though Strolll said more than £1m of investor funding sits alongside the grant.
That mix — debt, grant and equity in a single financing — lets a pre-commercial medtech fund capital-intensive validation work without repricing the cap table. IW Capital returning as lead in consecutive rounds also points to a stable ownership position rather than a change of control at the top of the register.
The £3.6m loan is earmarked for StrolllAssessment, a platform pairing AI with a fully equipped biomechanics lab that mirrors real-world rehabilitation settings. The company will build the lab at its Stafford office. By running multiple validation studies concurrently and automating the clinical validation of digital neuromotor assessments, Strolll argues it can compress a process that traditionally takes years into months.
The £700k grant, combined with the investor money, funds StrolllAcute, a bedside-first AR rehabilitation system for acute, bed-bound patients. The company says it enables early therapeutic intervention without altering ward workflows or adding to staff workload.
"Our team is committed to revolutionising rehabilitation for those living with neurological disorders," said Jorgen Ellis, chief executive and co-founder. "This funding will help us accelerate our mission to increase patient engagement, support progression and help clinicians deliver effective neurorehabilitation to a wider patient population."
Scott O'Brien, chief investment officer at Innovate UK, said Strolll had won backing across two innovations because it had "proven both its technical excellence and a credible route to commercial success", adding that combining debt finance with grant and private capital showed how the agency de-risks later-stage innovation.
The presence of Cleveland Clinic on the register is a commercial signal as much as a financial one, giving Strolll a route into one of the largest health systems in the United States. Future Planet Capital Regional's involvement reflects the continued weight of regional funds in West Midlands deal flow, where non-London medtech rounds still lean heavily on public and quasi-public capital.
Original source: EU-Startups
